Summary

Market Analysis and Insights: Global Gene Therapy on Cardiovascular Disease Market
The global Gene Therapy on Cardiovascular Disease market size is projected to reach US$ 984.21 million by 2027, from US$ 0.54 million in 2020, at a CAGR of 105.42% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Therapy on Cardiovascular Disease market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Therapy on Cardiovascular Disease market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy on Cardiovascular Disease market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy on Cardiovascular Disease market.
Global Gene Therapy on Cardiovascular Disease Scope and Market Size
Gene Therapy on Cardiovascular Disease market is segmented by players, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global Gene Therapy on Cardiovascular Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and By Application in terms of revenue and forecast for the period 2016-2027.

By Company
Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis

Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy

Segment by Application
Heart Disease
Vascular Disease

ページTOPに戻る

Table of Contents

1 REPORT OVERVIEW 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Gene Therapy on Cardiovascular Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1
1.2.2 Viral Gene Therapy 3
1.2.3 Non-Viral Gene Therapy 3
1.3 Market by Application 4
1.3.1 Global Gene Therapy on Cardiovascular Disease Market Share by Application: 2016 VS 2021 VS 2027 5
1.3.2 Heart Disease 5
1.3.3 Vascular Disease 6
1.4 Study Objectives 6
1.5 Years Considered 7
2 GLOBAL GROWTH TRENDS 8
2.1 Global Gene Therapy on Cardiovascular Disease Market Perspective (2016-2027) 8
2.2 Gene Therapy on Cardiovascular Disease Industry Dynamic 9
2.2.1 Gene Therapy on Cardiovascular Disease Market Trends 9
2.2.2 Gene Therapy on Cardiovascular Disease Market Drivers 10
2.2.3 Gene Therapy on Cardiovascular Disease Market Challenges 10
2.2.4 Gene Therapy on Cardiovascular Disease Market Restraints 11
3 COMPETITION LANDSCAPE BY KEY PLAYERS 12
3.1 Global Top Gene Therapy Players by Revenue 12
3.1.1 Global Top Gene Therapy Players by Revenue (2019-2020) 12
3.1.2 Global Gene Therapy Revenue Market Share by Players (2019-2020) 12
3.2 Key Players Gene Therapy Product Solution and Service 13
3.3 Gene Therapy on Cardiovascular Disease Key Players Head office 13
3.4 Pipeline of Gene Therapy on Cardiovascular Disease Company 14
3.5 Mergers & Acquisitions, Expansion Plans 14
4 GENE THERAPY ON CARDIOVASCULAR DISEASE BREAKDOWN DATA BY TYPE 19
4.1 Global Gene Therapy on Cardiovascular Disease Historic Market Size by Type (2016-2021) 19
4.2 Global Gene Therapy on Cardiovascular Disease Forecasted Market Size by Type (2022-2027) 20
5 GENE THERAPY ON CARDIOVASCULAR DISEASE BREAKDOWN DATA BY APPLICATION 22
5.1 Global Gene Therapy on Cardiovascular Disease Historic Market Size by Application (2016-2021) 22
5.2 Global Gene Therapy on Cardiovascular Disease Forecasted Market Size by Application (2022-2027) 22
6 KEY GENE THERAPY ON CARDIOVASCULAR DISEASE PLAYERS PROFILES 24
6.1 Renovacor 24
6.1.1 Renovacor Company Details 24
6.1.2 Renovacor Business Overview 24
6.1.3 Renovacor Gene Therapy on Cardiovascular Disease Introduction 25
6.1.4 Renovacor Recent Development 25
6.2 Gene Biotherapeutics 26
6.2.1 Gene Biotherapeutics Company Details 26
6.2.2 Gene Biotherapeutics Business Overview 27
6.2.3 Gene Biotherapeutics Gene Therapy on Cardiovascular Disease Introduction 27
6.2.4 Gene Biotherapeutics Recent Development 28
6.3 AskBio 28
6.3.1 AskBio Company Details 28
6.3.2 AskBio Business Overview 29
6.3.3 AskBio Gene Therapy on Cardiovascular Disease Introduction 30
6.3.4 AskBio Recent Development 30
6.4 Novartis 31
6.4.1 Novartis Details 31
6.4.2 Novartis Major Business Analysis 31
6.4.3 Novartis Gene Therapy on Cardiovascular Disease Product and Solutions 32
6.5 Human Stem Cells Institute 33
6.5.1 Human Stem Cells Institute Details 33
6.5.2 Human Stem Cells Institute Major Business Analysis 33
6.5.3 Human Stem Cells Institute Gene Therapy on Cardiovascular Disease Product and Solutions 34
7 KEY GENE THERAPY PLAYERS PROFILES 35
7.1 Biogen 35
7.1.1 Biogen Details 35
7.1.2 Biogen Major Business Analysis 35
7.1.3 Biogen Gene Therapy Product and Solutions 36
7.1.4 Biogen Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 37
7.2 Novartis 37
7.2.1 Novartis Details 37
7.2.2 Novartis Major Business Analysis 38
7.2.3 Novartis Gene Therapy Product and Solutions 38
7.2.4 Novartis Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 39
7.3 Gilead Sciences 40
7.3.1 Gilead Sciences Details 40
7.3.2 Gilead Sciences Major Business Analysis 40
7.3.3 Gilead Sciences Gene Therapy Product and Solutions 41
7.3.4 Gilead Sciences Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 41
7.4 Sarepta Therapeutics 42
7.4.1 Sarepta Therapeutics Details 42
7.4.2 Sarepta Therapeutics Major Business Analysis 42
7.4.3 Sarepta Therapeutics Gene Therapy Product and Solutions 43
7.4.4 Sarepta Therapeutics Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 43
7.5 Alnylam Pharmaceuticals 44
7.5.1 Alnylam Pharmaceuticals Details 44
7.5.2 Alnylam Pharmaceuticals Major Business Analysis 44
7.5.3 Alnylam Pharmaceuticals Gene Therapy Product and Solutions 45
7.5.4 Alnylam Pharmaceuticals Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 45
7.6 Amgen 46
7.6.1 Amgen Details 46
7.6.2 Amgen Major Business Analysis 46
7.6.3 Amgen Gene Therapy Product and Solutions 47
7.6.4 Amgen Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 47
7.7 Spark Therapeutics 47
7.7.1 Spark Therapeutics Details 47
7.7.2 Spark Therapeutics Major Business Analysis 48
7.7.3 Spark Therapeutics Gene Therapy Product and Solutions 48
7.7.4 Spark Therapeutics Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 49
7.8 Akcea Therapeutics 49
7.8.1 Akcea Therapeutics Details 49
7.8.2 Akcea Therapeutics Major Business Analysis 50
7.8.3 Akcea Therapeutics Gene Therapy Product and Solutions 50
7.8.4 Akcea Therapeutics Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 51
7.9 Bluebird bio 51
7.9.1 Bluebird bio Details 51
7.9.2 Bluebird bio Major Business Analysis 52
7.9.3 Bluebird bio Gene Therapy Product and Solutions 52
7.9.4 Bluebird bio Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 53
7.10 Sunway Biotech 53
7.10.1 Sunway Biotech Details 53
7.10.2 Sunway Biotech Major Business Analysis 54
7.10.3 Sunway Biotech Gene Therapy Product and Solutions 54
7.10.4 Sunway Biotech Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 54
7.11 SIBIONO 55
7.11.1 SIBIONO Details 55
7.11.2 SIBIONO Major Business Analysis 55
7.11.3 SIBIONO Gene Therapy Product and Solutions 56
7.11.4 SIBIONO Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 56
7.12 AnGes 57
7.12.1 AnGes Details 57
7.12.2 AnGes Major Business Analysis 57
7.12.3 AnGes Gene Therapy Product and Solutions 57
7.12.4 AnGes Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 58
7.13 Orchard Therapeutics 59
7.13.1 Orchard Therapeutics Details 59
7.13.2 Orchard Therapeutics Major Business Analysis 59
7.13.3 Orchard Therapeutics Gene Therapy Product and Solutions 60
7.13.4 Orchard Therapeutics Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 60
7.14 Human Stem Cells Institute 60
7.14.1 Human Stem Cells Institute Details 60
7.14.2 Human Stem Cells Institute Major Business Analysis 61
7.14.3 Human Stem Cells Institute Gene Therapy Product and Solutions 61
7.14.4 Human Stem Cells Institute Gene Therapy Revenue, Gross Margin and Market Share (2019-2020) 62
8 ANALYST'S VIEWPOINTS/CONCLUSIONS 63
9 APPENDIX 65
9.1 Research Methodology 65
9.1.1 Methodology/Research Approach 65
9.1.2 Data Source 68
9.2 Disclaimer 71
9.3 Author Details 71






Table 1. Global Gene Therapy on Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2016 VS 2021 VS 2027 1
Table 2. Key Players of Viral Gene Therapy 3
Table 3. Key Players of Non-Viral Gene Therapy 4
Table 4. Global Gene Therapy on Cardiovascular Disease Market Size Growth by Application (US$ Million): 2016 VS 2020 VS 2027 5
Table 5. Gene Therapy on Cardiovascular Disease Market Trends 9
Table 6. Gene Therapy on Cardiovascular Disease Market Drivers 10
Table 7. Gene Therapy on Cardiovascular Disease Market Challenges 10
Table 8. Gene Therapy on Cardiovascular Disease Market Restraints 11
Table 9. Global Gene Therapy Revenue by Players (2019-2020) & (US$ Million) 12
Table 10. Global Gene Therapy Market Share by Players (2019-2020) 12
Table 11. Key Players Gene Therapy Product Solution and Service 13
Table 12. Key Players Headquarters and Founded Time 13
Table 13. Pipeline of Gene Therapy on Cardiovascular Disease Company 14
Table 14. Mergers & Acquisitions, Expansion Plans 14
Table 15. Global Gene Therapy on Cardiovascular Disease Market Size by Type (2016-2021) & (US$ Million) 19
Table 16. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Type (2016-2021) 19
Table 17. Global Gene Therapy on Cardiovascular Disease Forecasted Market Size by Type (2022-2027) & (US$ Million) 20
Table 18. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Type (2022-2027) 20
Table 19. Global Gene Therapy on Cardiovascular Disease Market Size by Application (2016-2021) & (US$ Million) 22
Table 20. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Application (2016-2021) 22
Table 21. Global Gene Therapy on Cardiovascular Disease Forecasted Market Size by Application (2022-2027) & (US$ Million) 22
Table 22. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Application (2022-2027) 23
Table 23. Renovacor Company Details 24
Table 24. Renovacor Business Overview 24
Table 25. Renovacor Gene Therapy on Cardiovascular Disease Product 25
Table 26. Renovacor Recent Development 25
Table 27. Gene Biotherapeutics Company Details 26
Table 28. Gene Biotherapeutics Business Overview 27
Table 29. Gene Biotherapeutics Gene Therapy on Cardiovascular Disease Product 27
Table 30. Gene Biotherapeutics Recent Development 28
Table 31. AskBio Company Details 28
Table 32. AskBio Business Overview 29
Table 33. AskBio Gene Therapy on Cardiovascular Disease Product 30
Table 34. AskBio Recent Development 30
Table 35. Novartis Corporate Information 31
Table 36. Novartis Major Business 31
Table 37. Novartis Gene Therapy on Cardiovascular Disease Product and Solutions 32
Table 38. Human Stem Cells Institute Corporate Information 33
Table 39. Human Stem Cells Institute Major Business 33
Table 40. Human Stem Cells Institute Gene Therapy on Cardiovascular Disease Product and Solutions 34
Table 41. Biogen Corporate Information 35
Table 42. Biogen Major Business 35
Table 43. Biogen Gene Therapy Product and Solutions 36
Table 44. Biogen Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 37
Table 45. Novartis Corporate Information 37
Table 46. Novartis Major Business 38
Table 47. Novartis Gene Therapy Product and Solutions 38
Table 48. Novartis Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 39
Table 49. Gilead Sciences Corporate Information 40
Table 50. Gilead Sciences Major Business 40
Table 51. Gilead Sciences Gene Therapy Product and Solutions 41
Table 52. Gilead Sciences Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 41
Table 53. Sarepta Therapeutics Corporate Information 42
Table 54. Sarepta Therapeutics Major Business 42
Table 55. Sarepta Therapeutics Gene Therapy Product and Solutions 43
Table 56. Sarepta Therapeutics Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 43
Table 57. Alnylam Pharmaceuticals Corporate Information 44
Table 58. Alnylam Pharmaceuticals Major Business 44
Table 59. Alnylam Pharmaceuticals Gene Therapy Product and Solutions 45
Table 60. Alnylam Pharmaceuticals Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 45
Table 61. Amgen Corporate Information 46
Table 62. Amgen Major Business 46
Table 63. Amgen Gene Therapy Product and Solutions 47
Table 64. Amgen Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 47
Table 65. Spark Therapeutics Corporate Information 47
Table 66. Spark Therapeutics Major Business 48
Table 67. Spark Therapeutics Gene Therapy Product and Solutions 48
Table 68. Spark Therapeutics Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 49
Table 69. Akcea Therapeutics Corporate Information 49
Table 70. Akcea Therapeutics Major Business 50
Table 71. Akcea Therapeutics Gene Therapy Product and Solutions 50
Table 72. Akcea Therapeutics Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 51
Table 73. Bluebird bio Corporate Information 51
Table 74. Bluebird bio Major Business 52
Table 75. Bluebird bio Gene Therapy Product and Solutions 52
Table 76. Bluebird bio Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 53
Table 77. Sunway Biotech Corporate Information 53
Table 78. Sunway Biotech Major Business 54
Table 79. Sunway Biotech Gene Therapy Product and Solutions 54
Table 80. Sunway Biotech Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 54
Table 81. SIBIONO Corporate Information 55
Table 82. SIBIONO Major Business 55
Table 83. SIBIONO Gene Therapy Product and Solutions 56
Table 84. SIBIONO Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 56
Table 85. AnGes Corporate Information 57
Table 86. AnGes Major Business 57
Table 87. AnGes Gene Therapy Product and Solutions 57
Table 88. AnGes Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 58
Table 89. Orchard Therapeutics Corporate Information 59
Table 90. Orchard Therapeutics Major Business 59
Table 91. Orchard Therapeutics Gene Therapy Product and Solutions 60
Table 92. Orchard Therapeutics Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 60
Table 93. Human Stem Cells Institute Corporate Information 60
Table 94. Human Stem Cells Institute Major Business 61
Table 95. Human Stem Cells Institute Gene Therapy Product and Solutions 61
Table 96. Human Stem Cells Institute Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2020) 62
Table 97. Research Programs/Design for This Report 65
Table 98. Key Data Information from Secondary Sources 69
Table 99. Key Data Information from Primary Sources 70



List of Figures

Figure 1. Global Gene Therapy on Cardiovascular Disease Market Share by Type: 2020 2
Figure 2. Global Gene Therapy on Cardiovascular Disease Market Share by Type: 2027 2
Figure 3. Viral Gene Therapy Features 3
Figure 4. Non-Viral Gene Therapy Features 4
Figure 5. Global Gene Therapy on Cardiovascular Disease Market Share by Application: 2027 5
Figure 6. Gene Therapy on Cardiovascular Disease Report Years Considered 7
Figure 7. Global Gene Therapy on Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2016-2027 8
Figure 8. Global Gene Therapy on Cardiovascular Disease Market Size, (US$ Million), 2016 VS 2021 VS 2027 9
Figure 9. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Type (2016-2021) 20
Figure 10. Global Gene Therapy on Cardiovascular Disease Revenue Market Share by Type (2022-2027) 21
Figure 11. Bottom-up and Top-down Approaches for This Report 67
Figure 12. Data Triangulation 68
Figure 13. Key Executives Interviewed 70